Abstract:<h3 class="Heading">Purpose</h3><p class="Para">To compare annotation segmentation approaches and to assess the value of radiomics analysis applied to diffusion-weighted imaging (DWI) for evaluation of breast cancer receptor status and molecular subtyping.</p><h3 class="Heading">Procedures</h3><p class="Para">In this IRB-approved HIPAA-compliant retrospective study, 91 patients with treatment-naïve breast malignancies proven by image-guided breast biopsy, (luminal A, <em class="EmphasisTypeItalic">n</em> = 49; luminal B, <em class="EmphasisTypeItalic">n</em> = 8; human epidermal growth factor receptor 2 [HER2]-enriched, <em class="EmphasisTypeItalic">n</em> = 11; triple negative [TN], <em class="EmphasisTypeItalic">n</em> = 23) underwent multiparametric magnetic resonance imaging (MRI) of the breast at 3 T with dynamic contrast-enhanced MRI, T2-weighted and DW imaging. Lesions were manually segmented on high b-value DW images and segmentation ROIS were propagated to apparent diffusion coefficient (ADC) maps. In addition in a subgroup (<em class="EmphasisTypeItalic">n</em> = 79) where lesions were discernable on ADC maps alone, these were also directly segmented there. To derive radiomics signatures, the following features were extracted and analyzed: first-order histogram (HIS), co-occurrence matrix (COM), run-length matrix (RLM), absolute gradient, autoregressive model (ARM), discrete Haar wavelet transform (WAV), and lesion geometry. Fisher, probability of error and average correlation, and mutual information coefficients were used for feature selection. Linear discriminant analysis followed by k-nearest neighbor classification with leave-one-out cross-validation was applied for pairwise differentiation of receptor status and molecular subtyping. Histopathologic results were considered the gold standard.</p><h3 class="Heading">Results</h3><p class="Para">For lesion that were segmented on DWI and segmentation ROIs were propagated to ADC maps the following classification accuracies > 90% were obtained: luminal B <em class="EmphasisTypeItalic">vs.</em> HER2-enriched, 94.7 % (based on COM features); luminal B <em class="EmphasisTypeItalic">vs.</em> others, 92.3 % (COM, HIS); and HER2-enriched <em class="EmphasisTypeItalic">vs.</em> others, 90.1 % (RLM, COM). For lesions that were segmented directly on ADC maps, better results were achieved yielding the following classification accuracies: luminal B <em class="EmphasisTypeItalic">vs.</em> HER2-enriched, 100 % (COM, WAV); luminal A <em class="EmphasisTypeItalic">vs.</em> luminal B, 91.5 % (COM, WAV); and luminal B <em class="EmphasisTypeItalic">vs.</em> others, 91.1 % (WAV, ARM, COM).</p><h3 class="Heading">Conclusions</h3><p class="Para">Radiomic signatures from DWI with ADC mapping allows evaluation of breast cancer receptor status and molecular subtyping with high diagnostic accuracy. Better classification accuracies were obtained when breast tumor segmentations could be performed on ADC maps.</p>

Standardization and advancements efforts in breast diffusion-weighted imaging

Limited role of DWI with apparent diffusion coefficient mapping in breast lesions presenting as non-mass enhancement on dynamic contrast-enhanced MRI

Improving the image quality of DWI in breast cancer: comparison of multi-shot DWI using multiplexed sensitivity encoding to conventional single-shot echo-planar imaging DWI

Diffusion-Weighted MRI for the Assessment of Molecular Prognostic Biomarkers in Breast Cancer

Progresses of MRI diagnosis in breast cancer

Six DWI questions you always wanted to know but were afraid to ask: clinical relevance for breast diffusion MRI

Application of 3.0T-MRI DWI in evaluating the efficacy of synchronous radiotherapy and chemotherapy for advanced lung cancer

The road to breast cancer screening with diffusion MRI

Advances and challenges of MRI in breast

Recent Progress of Diffusion Weighted Magnetic Resonance Imaging in Assessment of Tumor in the Body

Prediction and Prognosis of Biologically Aggressive Breast Cancers by the Combination of DWI/DCE-MRI and Immunohistochemical Tumor Markers.

Optimizing Image Quality with High-Resolution, Deep-Learning-Based Diffusion-Weighted Imaging in Breast Cancer Patients at 1.5 T

Advanced Diffusion-Weighted MRI for Cancer Microstructure Assessment in Body Imaging, and Its Relationship With Histology

Diffusion-Weighted Imaging in Abdominal Oncology

Diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer

The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence?

Current Status and New Developments in Breast MRI

Ultra-High b-Value Diffusion-Weighted Imaging-Based Abbreviated Protocols for Breast Cancer Detection

Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes

A survey by the European Society of Breast Imaging on the implementation of breast diffusion-weighted imaging in clinical practice

Advanced breast diffusion-weighted imaging: what are the next steps? A proposal from the EUSOBI International Breast Diffusion-weighted Imaging working group